Swedbank Ab Horizon Therapeutics Public LTD CO Transaction History

Swedbank Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 09, 2024	SELL	$0.0 - $116.3 $0 - $90.3 Million	-776,494 Closed	0 $0
Q3 2023 Dec 09, 2024	BUY	$98.98 - $115.74 $227,654 - $266,202	2,300 Added 0.3%	776,494 $89.8 Million
Q2 2023 Dec 09, 2024	SELL	$96.34 - $112.38 $30.5 Million - $35.6 Million	-316,900 Reduced 29.04%	774,194 $79.6 Million
Q1 2023 Dec 09, 2024	SELL	$107.32 - $113.5 $1.85 Million - $1.95 Million	-17,200 Reduced 1.55%	1,091,094 $119 Million
Q4 2022 Dec 09, 2024	SELL	$62.39 - $113.8 $24.7 Million - $45 Million	-395,300 Reduced 26.29%	1,108,294 $126 Million
Q3 2022 Dec 09, 2024	BUY	$58.92 - $84.67 $18.3 Million - $26.3 Million	310,700 Added 26.05%	1,503,594 $93.1 Million
Q2 2022 Dec 09, 2024	BUY	$79.4 - $116.36 $42.4 Million - $62.2 Million	534,400 Added 81.15%	1,192,894 $95.1 Million
Q1 2022 Dec 09, 2024	BUY	$86.42 - $109.81 $1.72 Million - $2.18 Million	19,894 Added 3.12%	658,494 $69.3 Million
Q2 2021 Dec 09, 2024	BUY	$86.24 - $95.92 $1.79 Million - $1.99 Million	20,700 Added 3.35%	638,600 $59.8 Million
Q1 2021 Dec 09, 2024	BUY	$71.83 - $95.48 $44.4 Million - $59 Million	617,900 New	617,900 $56.9 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

Stay updated on Swedbank Ab with notifications on news.